FDA guidance
Bismuth Subsalicylate; Metronidazole; Tetracycline Hydrochloride (Tablet, Chewable…
FDA guidance · Draft · issued Feb 16, 2023
Key facts
| Title | Bismuth Subsalicylate; Metronidazole; Tetracycline Hydrochloride (Tablet, Chewable, Tablet, Capsule - Oral) |
|---|---|
| Status | Draft |
| Issue date | Feb 16, 2023 |
| Center | Center for Drug Evaluation and Research |
| Regulated product | Drugs |
| Topics | Product-Specific Guidance |
| Document on fda.gov | accessdata.fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents